We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Fulgent Genetics, Inc. (FLGT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Fulgent Genetics, Inc. is one of 1165 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Fulgent Genetics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for FLGT's full-year earnings has moved 27.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that FLGT has returned about 4.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.2% on average. This shows that Fulgent Genetics, Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adaptive Biotechnologies (ADPT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.3%.
Over the past three months, Adaptive Biotechnologies' consensus EPS estimate for the current year has increased 4.8%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Fulgent Genetics, Inc. is a member of the Medical Info Systems industry, which includes 48 individual companies and currently sits at #97 in the Zacks Industry Rank. This group has gained an average of 44.9% so far this year, so FLGT is slightly underperforming its industry in this area.
On the other hand, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry. This 553-stock industry is currently ranked #90. The industry has moved -5.3% year to date.
Fulgent Genetics, Inc. and Adaptive Biotechnologies could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Fulgent Genetics, Inc. (FLGT - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Fulgent Genetics, Inc. is one of 1165 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Fulgent Genetics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for FLGT's full-year earnings has moved 27.7% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that FLGT has returned about 4.5% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.2% on average. This shows that Fulgent Genetics, Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Adaptive Biotechnologies (ADPT - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 10.3%.
Over the past three months, Adaptive Biotechnologies' consensus EPS estimate for the current year has increased 4.8%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Fulgent Genetics, Inc. is a member of the Medical Info Systems industry, which includes 48 individual companies and currently sits at #97 in the Zacks Industry Rank. This group has gained an average of 44.9% so far this year, so FLGT is slightly underperforming its industry in this area.
On the other hand, Adaptive Biotechnologies belongs to the Medical - Biomedical and Genetics industry. This 553-stock industry is currently ranked #90. The industry has moved -5.3% year to date.
Fulgent Genetics, Inc. and Adaptive Biotechnologies could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.